胸腺上皮性肿瘤WHO简化病理分型的MSCT表现

目的:分析胸腺上皮性肿瘤(TET)的多层螺旋CT(MSCT)表现及多平面重组(MPR)特征,并探讨其与WHO简化病理分型之间的相关性。方法:回顾性分析40例经手术病理证实的TET患者术前MSCT及MPR图像,并与WHO简化病理分型[低危型胸腺瘤(A、AB、B1)、高危型胸腺瘤(B2、B3)与胸腺癌]进行比较。结果:高危型胸腺瘤与胸腺癌MSCT及MPR征象表现为肿瘤边缘不光整或分叶、形态不规则且强化后瘤内密度不均,以及对邻近结构侵犯,与低危型胸腺瘤有统计学差异﹙P<0.05﹚,胸腺癌纵隔淋巴结增大及远处转移较两组胸腺瘤更为常见,而患者的年龄、性别、肿瘤体积以及瘤内钙化在三组间比较均无明显统计学差异。结论:MSCT扫描及MPR技术对TET的WHO简化病理分型鉴别诊断具有重要价值,为临床治疗方案的选择及判断预后提供信息。     

MSCT对胸腺上皮肿瘤WHO简化病理分型的鉴别诊断价值

目的探讨多层螺旋CT(MSCT)对低危型、高危型胸腺瘤及胸腺癌的鉴别诊断价值。方法回顾性分析经病理(穿刺或手术)证实的67例胸腺上皮肿瘤,基于WHO病理分型简化为低危型胸腺瘤、高危型胸腺瘤及胸腺癌三组,并对其CT征象进行统计分析。结果67例TETs中,低危型胸腺瘤30例(A型3例、AB型20例、B1型7例),高危型胸腺瘤22例(B2型11例、B3型11例),胸腺癌15例。高危型胸腺瘤、胸腺癌较低危型胸腺瘤易表现为边缘分叶或不规则(P均<0.05)及易出现对心包侵犯(P均<0.05);胸腺癌较低危型胸腺瘤易出现增强后密度不均、囊变坏死及胸膜转移(P均≤0.003);胸腺癌较低危型、高危型胸腺瘤易出现纵隔淋巴结肿大(P均≤0.002);纵隔大血管侵犯在三组间两两比较均有统计学差异(P均<0.05)。结论MSCT对TETs的WHO简化病理分型鉴别诊断具有重要价值。     

MSCT对低危型、高危型胸腺瘤及胸腺癌的鉴别诊断价值

【摘要】目的：探讨MSCT对低危型、高危型胸腺瘤及胸腺癌的鉴别诊断价值。方法：将68例经穿刺或手术病理证实的胸腺上皮性肿瘤（TETs）,按WHO简化病理分型分为低危型胸腺瘤、高危型胸腺瘤和胸腺癌三组,对三组的MSCT征象进行统计学分析。结果：68例TETs中,低危型胸腺瘤31例（A型4例、AB型19例、B1型8例）、高危型胸腺瘤15例（B2型9例、B3型6例）、胸腺癌22例。高危型胸腺瘤、胸腺癌均较低危型胸腺瘤更易表现为肿瘤边缘不规则或分叶（P均<0.05);高危型胸腺瘤、胸腺癌均较低危型胸腺瘤更易出现对胸膜/心包、邻近大血管侵犯（P均<0.05）;增强后密度不均及囊变坏死率在胸腺癌和低危型胸腺瘤间均具有显著性差异（P均<0.001）;胸腺癌出现纵隔淋巴结转移较低危型、高危型胸腺瘤更为常见（P<0.05）;而瘤内钙化在三者间两两比较均无明显统计学差异（P均>0.05）。结论：MSCT对WHO简化病理分型的TETs具有一定的鉴别诊断价值。     

小于等于3厘米实性周围型肺癌的MSCT表现

目的 总结≤3 cm实性周围型肺癌的MSCT 征象,以提高肺癌的影像诊断水平.方法 回顾性分析105例病理证实的3 cm以下实性肺癌的基本临床资料、病灶大小及MSCT征象(病灶形态、边缘形态、瘤肺界面、内部结构及邻近结构);用Fisher确切概率法、R×C列联表χ2检验、χ2分割法、非参数Mann-Whitney U、 Kruskal-Wallis检验进行统计学分析.结果 105例结节中圆形或类圆形 101例(96.19%),瘤肺界面清楚毛糙100例(95.24%),分叶85例(80.95%),毛刺60例(57.14%),棘状突起33例(31.43%),空泡征12例(11.43%),支气管扩张扭曲或截断的共55例(52.38%),胸膜凹陷征59例(56.19%),血管集束征35例(33.33%).≤1 cm肺癌的分叶(12例)明显低于2～≤3 cm组(29例) (χ2值=8.13,P＜0.0125).鳞癌的男女比例(14GA9552)及病灶大小(2.12 cm±0.63 cm)均高于腺癌(45GA95542、1.72 cm±0.62 cm)(P=0.008 vs 0.032＜0.05).腺癌与鳞癌间仅胸膜凹陷征有统计学差异(54例vs 4例,χ2值7.55,P=0.006＜0.05).结论 3 cm以下实性周围型肺癌具有一定的MSCT特征.     

胸腺瘤MSCT征象与PCNA及MMP-2表达的相关性

目的:探讨胸腺瘤MSCT征象与增殖细胞核抗原(PCNA)、基质金属蛋白酶2(MMP-2)在胸腺瘤组织中表达的相关性。方法:对46例胸腺瘤患者行MSCT平扫,其中21例行增强扫描,所有胸腺瘤标本行免疫组化SP法染色,分析MSCT征象与PCNA、MMP-2表达水平的相关性。结果:胸腺瘤CT征象中的病灶直径大于10cm,分叶征,病灶边缘不光滑,纵膈脂肪线消失,胸膜、心包及大血管侵犯,纵隔淋巴结、远处转移及病灶高强化程度与胸腺瘤组织PCNA及MMP-2的高表达具有显著相关性(P<0.05)。结论:MSCT征象能在一定程度上反映胸腺瘤的病理学特点,有利于术前无创地评估肿瘤生物学行为。     

Correlation of PCNA and MMP-2 expression with multi-slice spiral CT manifestations of thymoma

目的:探讨胸腺瘤MSCT征象与增殖细胞核抗原(PCNA)、基质金属蛋白酶2(MMP-2)在胸腺瘤组织中表达的相关性.方法:对46例胸腺瘤患者行MSCT平扫,其中21例行增强扫描,所有胸腺瘤标本行免疫组化SP法染色,分析MSCT征象与PCNA、MMP-2表达水平的相关性.结果:胸腺瘤CT征象中的病灶直径大于10 cm,分叶征,病灶边缘不光滑,纵膈脂肪线消失,胸膜、心包及大血管侵犯,纵隔淋巴结、远处转移及病灶高强化程度与胸腺瘤组织PCNA及MMP-2的高表达具有显著相关性(P＜0.05).结论:MSCT征象能在一定程度上反映胸腺瘤的病理学特点,有利于术前无创地评估肿瘤生物学行为.     

胸腺上皮性肿瘤世界卫生组织组织学分型与CT影像表现的相关性研究

目的 探讨不同组织类型胸腺上皮性肿瘤(TET)的CT特征.方法 回顾性分析133例经手术病理证实TET的CT表现,并根据WHO 2004年标准对所有病例重新进行组织学分型,分析不同组织类型TET的CT特征.各类型间比较采用x2检验.结果 133例TET病理分型A、AB、B1、B2、B3型和胸腺癌分别为10、17、13、46、30和17例.A型(9例,90.0％)、AB型(15例,88.2％)、B1(10例,76.9％)和B2型(31例,67.4％)胸腺瘤多呈圆形或卵圆形,形状规则且边界光滑;而B3型(21例,70.0％)与胸腺癌(15例,88.2％)肿块呈不规则形或铸型生长,且边界不清楚.胸腺癌坏死囊变发生率最高(15例,88.2％),其次为B3型胸腺瘤(19例,63.3％)和A型胸腺瘤(6例,60.0％),B2和B3型胸腺瘤钙化发生率较高(32例,42.1％),明显高于其他类型TET(8例,14.0％;X2=12.20,P＜0.01).A、AB、B3型TET及胸腺癌高度强化的发生率(39例,52.7％),明显高于B1和B2型(8例,13.6％;x2= 22.01,P＜0.01).结论 根据WHO 2004标准,不同组织类型的TET的CT表现具有一定特征性,CT在一定程度上具有预测TET组织学类型、判断预后的潜力.     

无症状胸腺瘤CT影像特点与其型别的相关性研究

目的探讨无症状胸腺瘤CT影像特点与其型别的相关性。方法回顾性分析2013年2月~2017年2月收治的18例无症状胸腺瘤患者临床资料。依据2004年WHO组织分型标准,将18例患者分为低危组(A、AB和B1)、高危组(B2、B3)和胸腺癌(C)3个亚型组。分析CT表现与WHO组织分型的相关性。结果本组18例胸腺瘤患者包括A型1例(5.56%),AB型2例(11.11%),B1型4例(22.22%),B2型5例(27.78%),B3型4例(22.22%),胸腺癌2例(11.11%)。低危组、高危组9例和胸腺癌组在强化平均CT值、肿块边缘、肿块密度、侵犯纵隔胸膜、侵犯血管结构、侵犯心包和淋巴结转移方面比较存在显著性差异(P0.05)。结论胸腺瘤的CT表现与WHO组织分型具有十分紧密的关系,可通过CT表现肿瘤的边界、密度、周围组织侵犯和强化平均CT值等指标用于无症状胸腺瘤的WHO组织分型鉴别。     

胸腺上皮肿瘤WHO组织学分型与CT征象相关性分析

目的 探讨胸腺上皮肿瘤WHO组织学分型与CT征象的相关性.资料与方法 复习经手术病理证实为胸腺上皮肿瘤的63例患者术前的CT影像资料,按照2004年WHO组织学分型进行重新分型,将观测的CT征象与简化的组织学分型组(低危组胸腺瘤、高危组胸腺瘤、胸腺癌组)对照.结果 63例中,低危组胸腺瘤35例,高危组胸腺瘤16例,胸腺癌组12例.CT显示胸腺癌组更多见不规则轮廓、边缘毛糙/不清、纵隔脂肪层浑浊/消失、淋巴结肿大、胸膜受侵、其他脏器受侵和远处转移等征象;低危和高危组胸腺瘤更多见边缘光滑、分叶和类圆形轮廓、纵隔脂肪层清晰(P＜0.05).结论 不规则轮廓、边缘毛糙/不清、纵隔脂肪层浑浊/消失、淋巴结肿大、胸膜受侵、其他脏器受侵和远处转移应提示胸腺癌的诊断,而边缘光滑、分叶和类圆形轮廓、纵隔脂肪层清晰则提示低危组和高危组胸腺瘤的诊断.CT鉴别低危组和高危组胸腺瘤存在一定困难.     

胸腺上皮性肿瘤18F-FDG PET/CT显像最大标准化摄取值与WHO病理分型及Masaoka分期的关系

目的 探讨胸腺上皮性肿瘤（TET）术前18F-FDG PET/CT显像最大标准化摄取值（SUV_max）与世界卫生组织（WHO）病理分型及Masaoka分期的关系。 方法 回顾性分析2007年9月至2019年3月于南京医科大学第一附属医院经手术病理学结果证实的40例TET患者的临床资料，其中男性14例、女性26例，年龄32~79岁。分析所有患者的术前18F-FDG PET/CT显像资料，测定病灶的SUV_max。参照WHO(2015) TET病理分型将TET患者分为低危型胸腺瘤（A、AB、B1型）、高危型胸腺瘤（B2、B3型）和胸腺癌（C型）3组；采用Masaoka分期标准将TET患者分为Ⅰ期、Ⅱ期和Ⅲ期 3组；将TET患者分为胸腺瘤（包括低危型胸腺瘤和高危型胸腺瘤）和胸腺癌2组，采用受试者工作特征（ROC）曲线计算SUV_max和曲线下面积（AUC）。3组间的比较采用Kruskal-Wallis秩和检验，2组间的比较采用 Mann-Whitney U检验。 结果 低危型胸腺瘤11例（A型1例、AB型4例、B1型6例），高危型胸腺瘤15例（B2型10例、B3型5例），胸腺癌14例。Masaoka分期:Ⅰ期8例，Ⅱ期17例，Ⅲ期15例。低危型胸腺瘤、高危型胸腺瘤和胸腺癌的中位SUV_max分别为3.78、5.21和10.44，3组间SUV_max的差异有统计学意义（χ2=26.716，P<0.01）；组间的两两比较差异均有统计学意义（Z=3.088、?3.928、4.106，均P<0.01）。Ⅰ期、Ⅱ期、Ⅲ期的中位SUV_max分别为3.74、5.14、10.08，3组间SUV_max的差异有统计学意义（χ2=22.295，P<0.01），组间的两两比较差异均有统计学意义（Z=2.680、3.679、?3.644，均P<0.01）。ROC曲线分析结果:AUC为0.953（95%可变区间:0.891~1.000，P<0.01）；SUV_max=6.81是鉴别诊断胸腺瘤与胸腺癌的最佳临界值。 结论 18F-FDG PET/CT 的参数SUV_max与TET的WHO病理分型及Masaoka分期具有较好的相关性，可为临床制定治疗计划提供参考。     

18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups.

The purpose of our study was to assess the usefulness of integrated PET/CT using 18F-FDG for distinguishing thymic epithelial tumors according to the World Health Organization (WHO) classification. METHODS: Thirty-three patients (age range, 34-68 y; mean age, 54.6 y) with thymic epithelial tumors, who underwent both integrated PET/CT and enhanced CT, were included. The clinicopathologic stages, maximum standardized uptake values (SUVs), and uptake patterns of tumors on integrated PET/CT images, and various enhanced CT findings, are described according to the simplified (low-risk [types A, AB, and B1] and high-risk [types B2 and B3] thymomas and thymic carcinomas) subgroups of the WHO classification. Discriminant analysis was performed to determine the relative capabilities of integrated PET/CT and enhanced CT findings to differentiate tumor subgroups. RESULTS: Tumors included 8 low-risk thymomas, 9 high-risk thymomas, and 16 thymic carcinomas. The maximum SUVs of high-risk thymomas (P < 0.001) and low-risk thymomas (P < 0.001) were found to be significantly lower than those of thymic carcinomas. Homogeneous 18F-FDG uptake within tumors was more frequently seen in thymic carcinomas than in high-risk thymomas (P = 0.027) or low-risk thymomas (P = 0.001). The uptake pattern (homogeneous vs. heterogeneous) on integrated PET/CT images and the presence of mediastinal fat invasion on enhanced CT images were found to be useful for differentiating tumor subgroups. In addition, integrated PET/CT helped detect lymph node metastases, which were not identified on enhanced CT in 2 patients. CONCLUSION: Integrated PET/CT was found to be useful for differentiating subgroups of thymic epithelial tumors and for staging the extent of the disease.     

Thymic epithelial tumors: comparison of CT and MR imaging findings of low-risk thymomas, high-risk thymomas, and thymic carcinomas

OBJECTIVE: To assess the CT and magnetic resonance (MR) imaging findings of thymic epithelial tumors classified according to the current World Health Organization (WHO) histologic classification and to determine useful findings in differentiating the main subtypes. MATERIALS AND METHODS: Sixty patients with thymic epithelial tumor who underwent both CT and MR imaging were reviewed retrospectively. All cases were classified according to the 2004 WHO classification. The following findings were assessed in each case on both CT and MRI: size of tumor, contour, perimeter of capsule; homogeneity, presence of septum, hemorrhage, necrotic or cystic component within tumor; presence of mediastinal lymphadenopathy, pleural effusion, and great vessel invasion. These imaging characteristics of 30 low-risk thymomas (4 type A, 12 type AB, and 14 type B1), 18 high-risk thymomas (11 type B2 and seven type B3), and 12 thymic carcinomas on CT and MR imaging were compared using the chi-square test. Comparison between CT and MR findings was performed by using McNemar test. RESULTS: On both CT and MR imaging, thymic carcinomas were more likely to have irregular contours (P < .001), necrotic or cystic component (P < .05), heterogeneous contrast-enhancement (P < .05), lymphadenopathy (P < .0001), and great vessel invasion (P < .001) than low-risk and high-risk thymomas. On MR imaging, the findings of almost complete capsule, septum, and homogenous enhancement were more commonly seen in low-risk thymomas than high-risk thymomas and thymic carcinomas (P < .05). MR imaging was superior to CT in the depiction of capsule, septum, or hemorrhage within tumor (all comparison, P < .05). CONCLUSION: The presence of irregular contour, necrotic or cystic component, heterogeneous enhancement, lymphadenopathy, and great vessel invasion on CT or MR imaging are strongly suggestive of thymic carcinomas. On MR imaging, the findings of contour, capsule, septum, and homogenous enhancement are helpful in distinguishing low-risk thymomas from high-risk thymomas and thymic carcinomas.     

Does CT of thymic epithelial tumors enable us to differentiate histologic subtypes and predict prognosis?

OBJECTIVE: The aims of our study were to describe the CT findings of thymic epithelial tumors and to correlate these findings with the histopathologic subtypes and prognosis. MATERIALS AND METHODS: The CT findings of thymic epithelial tumors were analyzed in 91 patients who had undergone surgery between May 1995 and June 2002. Two observers, who were unaware of the histopathologic classification made in accordance with World Health Organization (WHO) recommendations and the prognosis of the tumors, retrospectively reviewed the initial CT findings in terms of the contours and shapes of the tumors and the presence of necrosis, calcification, mediastinal fat or great vessel invasion, pleural seeding, contrast enhancement, and lymph node enlargement. These findings were compared with the simplified subgroups of WHO histologic classification (low-risk thymomas [types A, AB, and B1], high-risk thymomas [types B2 and B3], and thymic carcinomas [type C]) and with postoperative recurrence. RESULTS: The study found 31 low-risk thymomas (eight type A, 16 type AB, and seven type B1 tumors), 45 high-risk thymomas (25 type B2 and 20 type B3), and 15 thymic carcinomas (type C). Lobulated contour was more often seen in high-risk thymomas (26/45, 58%; p = 0.0456) and thymic carcinomas (10/15, 67%; p = 0.033) than in low-risk thymomas (9/31, 29%). Mediastinal fat invasion was more often seen in thymic carcinomas (5/15, 33%; p = 0.0133) than in low-risk thymomas (1/31, 3%). Great vessel invasion was seen only in thymic carcinomas (2/15, 13%; p = 0.0244). Tumors with a lobulated or irregular contour, an oval shape, mediastinal fat or great vessel invasion, and pleural seeding showed significantly more frequent recurrence and metastasis (all, p < 0.05). CONCLUSION: Although CT is of limited value in differentiating histologic subtypes according to the WHO classification, CT findings may serve as predictors of postoperative recurrence or metastasis for the thymic epithelial tumors.     

胸腺上皮肿瘤WHO病理分型与CT特征的相关性

目的：探讨胸腺上皮性肿瘤（TETs）的WHO病理分型与CT表现的相关性,以提高其CT诊断及临床诊疗水平。方法：回顾性分析经穿刺活检或手术病理证实的66例TETs患者的CT影像学表现。所有患者均行胸部CT平扫及增强扫描,均经组织病理学及细胞免疫组化检查并进行WHO组织病理分型,分析TETs各种组织学类型的CT特征。结果：66例TETs中男39例,女27例,年龄6～77岁。病理分型：A型5例（7．6％）,AB型15例（22．7％）,B1型13例（19．7％）,B2型10例（15．2％）,B3型10例（15．2％）及胸腺癌13例（19．7％）。A、AB、B1型胸腺瘤均呈圆形或类圆形,而80．0％的B3型胸腺瘤及92．3％的胸腺癌呈不规则形;大部分（92．4％）胸腺肿瘤呈中度强化。80．0％B3型胸腺瘤及100％胸腺癌有包膜破坏并侵犯邻近结构;40．0％的B3型胸腺瘤及61．5％的胸腺癌出现心包和（或）胸膜腔积液;随着肿瘤病理分级的增加,周围结构受侵的发生率亦随之升高,分别为15．4％（B1）、40．0％（B2）、80．0％（B3）及100％（胸腺癌）。TETs组织学分类与侵袭危险度CT分级之间存在显著相关性（rs=0．736,P〈0．01）。结论：不同WHO病理分型的TETs的cT表现具有一定特征性,TETs的CT特征反映了其侵袭危险性及组织病理学分型。     

非小细胞肺癌MSCT征象与CD44v6表达间相关性研究

目的：探讨非小细胞肺癌（non-small cell lung cancer,NSCLC）的MSCT征象与CD44v6表达的相关性。方法：对40例经手术病理证实的NSCLC患者术前进行MSCT扫描,并用免疫组织化学法对肿瘤标本进行染色,检测CD44v6在肺癌组织、癌旁组织中的表达。结果：①CD44v6在肿块最大径〉3cm的肺癌组织中的表达与≤3cm肺癌组织中的表达无明显差异;MSCT上肿块轮廓出现分叶征、边缘出现短毛刺或棘状突起者,CD44v6阳性表达率明显增高;②CD44v6在淋巴结转移组肺癌中的表达高于无淋巴结转移组;③CD44v6在胸膜受累组肺癌中的表达高于胸膜未受累组;④CD44v6在肺癌组织中的表达显著高于癌旁组织（P〈0.05）。结论：NSCLC的MSCT征象与CD44v6表达具有重要关系;CD44v6的异常高表达可能在NSCLC的浸润和转移机制中起重要作用。     

Malignant thymic epithelial tumors: CT-pathologic correlation

OBJECTIVE: The purpose of our study was to describe and compare the CT and pathologic findings of atypical thymoma and thymic carcinoma. MATERIALS AND METHODS: Twenty-seven consecutive patients (14 men, 13 women ranging in age from 22 to 77 years [mean age, 52 years]) with pathologically proven atypical thymoma (n = 9) and thymic carcinoma (n = 18) constituted the study population. The chest CT findings in each of the 27 patients were reviewed retrospectively in consensus by two chest radiologists. These findings were correlated with pathologic findings. RESULTS: The tumors were located in the anterior mediastinum, and most tumors had a lobulated margin (24/27, 89%). Atypical thymomas were significantly smaller (mean, 4.7 cm) than thymic carcinomas (mean, 7.2 cm) (p = 0.041) on CT. The findings of invasion of the great vessels, lymph node enlargement, extrathymic metastases, and phrenic nerve palsy were seen only in patients with thymic carcinoma. The frequencies of necrosis, intratumoral calcification, pleural effusion, pleural implants, pericardial effusion, and obliteration of the mediastinal fat plane were not significantly different between atypical thymomas and thymic carcinomas (p > 0.05). Various histologic subtypes were included in thymic carcinoma. The tumor necrosis and calcification seen on CT were confirmed at pathologic examination. CONCLUSION: When a large thymic tumor appears with invasion of the great vessels, lymph node enlargement, phrenic nerve palsy, or extrathymic metastases on CT, thymic carcinoma rather than atypical thymoma should be considered.     

胸腺瘤的CT诊断

目的评估CT诊断良恶性胸腺瘤的价值.材料和方法分析31例经外科和病理证实的胸腺瘤的CT表现.结果良性胸腺瘤10例,除1例与左肺动脉局部有粘连外,其余边界均清晰.侵袭性胸腺瘤12例,胸腺癌9例,除1例鳞癌外,CT均为不规则肿块,血管间隙均受侵,前者心包受侵8例,胸膜受侵7例,后者心包受侵5例,胸膜受侵5例,肺转移4例,双肾上腺转移1例,胸骨破坏1例.结论CT能准确鉴别良性恶性胸腺瘤,显示恶性胸腺瘤的浸润范围,并对侵袭性胸腺瘤和胸腺癌进行鉴别.     

肺少见神经内分泌肿瘤的CT诊断（附38例分析）

目的:分析和总结肺少见神经内分泌肿瘤(TC、AC、LCNEC)的临床及CT征象,提高此类疾病的诊断准确性.方法:回顾性分析2011年3月-2017年2月在南京中医药大学附属医院及江苏省肿瘤医院经病理证实的38例肺少见神经内分泌肿瘤患者的临床及MSCT资料,其中典型类癌(TC) 12例、不典型类癌(AC) 11例、大细胞肺神经内分泌肿瘤(LCNEC) 15例.结果:(1)临床症状:三组TC患者的发病年龄最轻,LCNEC患者的发病年龄最大(P=0.000);LCNEC多有长期大量吸烟史(P=0.034).(2)瘤体征象:TC、AC均以中央型多见,TC好发于肺叶支气管,AC好发于肺段支气管;LCNEC以周围型多见,好发于胸膜下肺实质(P=0.000);TC病灶最小,LCNEC病灶最大(P=0.021);TC病灶以圆形或类圆形多见(P=0.032),LCNEC病灶形态多样,更易呈现狭长形改变(P=0.005);TC病灶边缘光滑锐利,LCNEC病灶边缘多有分叶征(P=0.001);TC强化程度最高;LCNEC坏死更多见(P=0.030),强化程度最低(P=0.012).(3)继发征象:TC较AC及LCNEC更易继发阻塞性肺不张(P=0.009);LCNEC更易出现肺门和/或纵隔淋巴结转移(P=0.003)及胸膜受累(P=0.000).(4)伴随征象:LCNEC更易合并弥漫性肺气肿等慢性肺部疾病改变(P=0.019).结论:肺少见神经内分泌肿瘤的MSCT表现具有一定的特征性,MSCT有助于本病的诊断和鉴别诊断.